Trial · NCT05006573
Results by group504
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 504
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period | Benralizumab 30 mg | 1.44 | 95% Confidence Interval 1.05 to 1.97 | exacerbations per year | |
| Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period | Placebo | 1.27 | 95% Confidence Interval 0.89 to 1.80 | exacerbations per year | |
| Time to First Exacerbation in the Double-blind Treatment Period | Benralizumab 30 mg | 233 | 95% Confidence Interval 118 to NA | days | |
| Time to First Exacerbation in the Double-blind Treatment Period | Placebo | 316 | 95% Confidence Interval 141 to NA | days | |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 2 | 6.6 | Standard Deviation 12.57 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 2 | 3.1 | Standard Deviation 11.65 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 4 | 5.8 | Standard Deviation 12.53 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 4 | -1.5 | Standard Deviation 12.49 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 6 | 6.8 | Standard Deviation 14.39 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 6 | 0.7 | Standard Deviation 10.94 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 8 | 6.6 | Standard Deviation 14.17 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 8 | 2.1 | Standard Deviation 16.29 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 10 | 5.3 | Standard Deviation 13.02 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 10 | -1.0 | Standard Deviation 14.46 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 12 | 7.2 | Standard Deviation 11.47 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 12 | 0.9 | Standard Deviation 15.44 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 14 | 8.0 | Standard Deviation 12.28 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 14 | 3.7 | Standard Deviation 14.63 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Benralizumab 30 mg | Week 16 | 6.2 | Standard Deviation 14.51 | score on a scale |
| Change From Baseline in QoL-B-RSS Over the Double-blind Period | Placebo | Week 16 | 1.3 | Standard Deviation 15.79 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05006573/results